Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

ClinicalTrials.gov ID: NCT05846646

Public ClinicalTrials.gov record NCT05846646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligometastatic NSCLC and RCC

Study identification

NCT ID
NCT05846646
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Enrollment
6 participants

Conditions and interventions

Interventions

  • IMSA101 Drug
  • Immune checkpoint inhibitor Drug
  • PULSAR Radiation

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 27, 2023
Primary completion
Sep 15, 2024
Completion
Sep 15, 2024
Last update posted
Oct 19, 2025

2023 – 2024

United States locations

U.S. sites
9
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
City of Hope Orange County Lennar Foundation Cancer Center Irvine California 92618
The University of Kansas Medical Center Kansas City Kansas 66160
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health New York New York 10016
Louis Stokes Cleveland VA Medical Center Cleveland Ohio 44106
MetroHealth Medical Center Cleveland Ohio 44109
Baylor College of Medicine Medical Center Houston Texas 77030
Huntsman Cancer Institute, University of Utah Salt Lake City Utah 84112
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05846646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 19, 2025 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05846646 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →